Health Care

Pfizer’s phase‑II success with tilrekimig shows promise for atopic dermatitis, while new Medicare pricing rules and value‑based contracts reshape pharma reimbursement.

Johnson & Johnson Q3 earnings reveal steady revenue growth, robust R&D spend, and a strategic push into oncology, while highlighting risks from regulatory pressure and fierce competition.

Danaher crowns Julie Sawyer Montgomery as president‑CEO, driving innovation, diagnostics, and operational excellence to strengthen its life‑sciences leadership and patient impact.

Boston Scientific shows steady growth with disciplined capital use, deep R&D in cardiology & neurovascular, and efficient supply‑chain boosts.

Explore the bullish consensus on arGEN‑X SE: 18 analysts rate it “buy,” target +27% ahead of FDA approval, but watch manufacturing and competitive risks.

IDEXX Laboratories boosts veterinary care with its CoVetAI AI scribe acquisition, enhancing diagnostics, workflow efficiency, and revenue potential.

Sonova’s new AI‑powered Phonak EON hearing‑aid line launches in 700 German GEERS stores, boosting sales, margins and patient experience.

FDA expands CAMZYOS® to treat symptomatic obstructive hypertrophic cardiomyopathy in patients 30 kg+, offering a non‑surgical, evidence‑based option for adults and children.

Roche’s VOYAGER study confirms Vabysmo’s real‑world 12‑week dosing, boosting value and pricing, while a CE‑marked newborn kit opens a $2.4 bn screening market, driving future growth.

Swiss equity markets dip, but Roche and Swiss Re thrive—discover how reimbursement reforms, digital health ROI, and cost‑saving strategies keep Swiss healthcare resilient.